Skip to main content

Table 3 Assessment of CSPG effects on microglia experimental groups

From: Perturbing chondroitin sulfate proteoglycan signaling through LAR and PTPσ receptors promotes a beneficial inflammatory response following spinal cord injury

Experimental group

Treatment

Cell plating (3 h post treatment)

M0 (no treatment)

1) PDL

2) PDL + CSPGs (5 μg/ml)

3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml)

ILP (10 μM) + ISP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

Y-27632 (ROCK inhibitor, 10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

TAT (20 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

IMP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

M1 (40 ng/ml TNFα + 50 ng/ml IFNγ)

1) PDL

2) PDL + CSPGs (5 μg/ml)

3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml)

ILP (10 μM) + ISP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

Y-27632 (ROCK inhibitor, 10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

TAT (20 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

IMP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

M2 (10 ng/ml IL10)

1) PDL

2) PDL + CSPGs (5 μg/ml)

3) PDL + CSPGs (5 μg/ml) + ChABC (0.1 U/ml)

ILP (10 μM) + ISP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

Y-27632 (ROCK inhibitor, 10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

TAT (20 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)

IMP (10 μM)

1) PDL

2) PDL + CSPGs (5 μg/ml)